SCHEMBL6315558

SCHEMBL6315558

Cc1ccsc1-c1noc(N)c1C(=O)NC1CCC(C(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.38
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 6/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
POLB P06746 1/20 0.34
MAPK14 Q16539 2/20 0.34
RAB9A P51151 5/20 0.34
GAA P10253 2/20 0.34
ATM Q13315 1/20 0.34
SMYD3 Q9H7B4 1/20 0.34
EPHX1 P07099 1/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
GLA P06280 1/20 0.33
PKM P14618 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317149 0.89 KMT2A (0.43) GHSRKMT2ASMN1; SMN2LMNANPC1
SCHEMBL6315866 0.89 KMT2A (0.46) KMT2ASMN1; SMN2LMNANPC1POLB
SCHEMBL6315616 0.88 KMT2A (0.47) KMT2ASMN1; SMN2LMNANPC1POLB
SCHEMBL6324296 0.88 KMT2A (0.47) KMT2ASMN1; SMN2LMNANPC1POLB
SCHEMBL6319880 0.82 RAB9A (0.40) GHSRKMT2ASMN1; SMN2LMNANPC1
SCHEMBL6317565 0.80 ALDH1A1 (0.51) KMT2ASMN1; SMN2LMNAPOLBGAA
SCHEMBL6314960 0.80 GAA (0.39) KMT2ASMN1; SMN2LMNANPC1POLB
SCHEMBL6317732 0.79 TAS1R3 (0.47) KMT2APOLBKDM4ETSHRMAPK1
SCHEMBL6316433 0.78 CA1 (0.39) GHSRKMT2ASMN1; SMN2LMNAPDGFRB
SCHEMBL6316337 0.78 TDP1 (0.46) GHSRKMT2ASMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GHSR 4103/4885KMT2A 1089/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.